Composition for promoting drug release of drug-delivery liposomes

Patent metadata

Field	Value
Publication number	US-12485092-B2
Application number	US-202318122284-A
Country	US
Kind code	B2
Filing date	Mar 16, 2023
Priority date	Mar 16, 2022
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

A composition for delivering a drug includes a drug carrying liposome carrying a drug in a liposome, and an empty liposome which does not carry the drug and includes phospholipid having a head and two fatty acid chains, wherein both of the two fatty acid chains comprises omega-3 fatty acids or their derivatives.

First claim

What is claimed is:

1 . A composition for delivering a drug, comprising
a membrane-modified liposome formed by bringing a liposome carrying a drug into contact with an empty liposome not carrying the drug, wherein empty liposome comprises a membrane comprised of phospholipid having a head and two fatty acid chains, wherein both of the two fatty acid chains comprises omega-3 fatty acids or their derivatives.

2 . The composition of claim 1 , wherein the omega-3 fatty acids are independently selected from the group consisting of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

3 . The composition of claim 1 , wherein the membrane of the empty liposome further includes at least one of cholesterol, oleic acid, phospholipids combined with oleic acid, or α-tocopherol.

4 . The composition of claim 1 , wherein the phospholipid having the omega-3 fatty acids or their derivatives is included in an amount of 40% or more by weight based on a total lipid weight of the empty liposome.

5 . The composition of claim 1 , wherein the empty liposome has a diameter of 20 nm to 400 nm.

6 . The composition of claim 1 , wherein the empty liposome is dispersed in a solution containing at least one selected from the group consisting of histidine, sucrose, hydroxyethylpiperazine ethanesufonic acid, sodium chloride, phosphate and dextrose.

7 . The composition according to claim 1 , wherein the liposome carrying the drug includes phospholipid of which two fatty acid chains are saturated fatty acids.

8 . The composition according to claim 7 , wherein the phospholipid of which the two fatty acid chains are the saturated fatty acids is independently selected from the group consisting of: hydrogenated soy phosphatidylcholine (HSPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), hydrogenated egg phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

9 . The composition according to claim 1 , wherein a weight ratio of a phospholipid in the liposome carrying the drug and the phospholipid of the empty liposome is 1:0.1 to 1.

10 . The composition according to claim 1 , wherein the membrane-modified liposome has a diameter of 70 nm to 500 nm.

11 . The composition according to claim 1 , wherein the drug is an anticancer agent.

12 . A method for delivering a drug in a subject, the method comprising:
administering the composition of claim 1 to the subject.

13 . A kit for delivering a drug, the kit comprising:
a liposome carrying a drug; and an empty liposome having a membrane comprising phospholipid having a head and two fatty acid chains, wherein both of the fatty acid chains comprise omega-3 fatty acids or their derivatives.

Assignees

• Univ Sejong Ind Acad Coop Foud
• Univ Ajou Ind Academic Coop Found

Inventors

• Lim Soo Jeong
• Kim Eun A
• Kim So Hee
• Choi Hyeon Gyeom

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/1277

  Preparation processes; Proliposomes · CPC title

• A61K31/704 Primary

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• A61K47/02

  Inorganic compounds · CPC title